{"id":"W4377093422","doi":"10.1161/circheartfailure.122.009837","title":"Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials","year":2023,"lang":"en","type":"article","venue":"Circulation Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ted Rogers Centre for Heart Research","funders":"National Heart, Lung, and Blood Institute; Relypsa; Vifor Pharma; Impulse Dynamics; Intercept Pharmaceuticals; Prothena; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Dexcom; Regeneron Pharmaceuticals; Emory University; Boston Scientific Corporation; University of Pittsburgh; United Therapeutics Corporation; Eli Lilly and Company; U.S. Department of Defense; Sanofi; National Institute on Aging; CSL Behring; Bristol-Myers Squibb; Allergan; AstraZeneca; Edwards Lifesciences; Amgen; Pfizer; Tenax Therapeutics; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Gilead Sciences; Eisai; Cytokinetics; Brigham and Women's Hospital","keywords":"Dapagliflozin; Ejection fraction; Medicine; Placebo; Heart failure; Internal medicine; Cardiology; Heart failure with preserved ejection fraction; Randomized controlled trial; Atrial fibrillation; Diabetes mellitus; Type 2 diabetes; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000440095,0.0002144504,0.0006858381,0.0002414788,0.0002624512,0.00009967393,0.00004663669,0.0001215728,0.00003743632],"category_scores_gemma":[0.00040101,0.0001606123,0.0002944075,0.001047216,0.00009951168,0.0002971362,0.0000715655,0.0001462208,0.00002414824],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004398818,"about_ca_system_score_gemma":0.00002579438,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002092127,"about_ca_topic_score_gemma":0.0003485536,"domain_scores_codex":[0.9982492,0.0002234067,0.0004788472,0.0004209988,0.0003807882,0.0002468112],"domain_scores_gemma":[0.9983163,0.0007707774,0.0002156805,0.0003946046,0.0001922633,0.0001103376],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0003549017,0.0005074461,0.8948648,0.0002193439,0.005912646,0.000003772736,0.003142875,0.001073726,0.06731999,0.0003260759,0.01289734,0.01337706],"study_design_scores_gemma":[0.002234223,0.0002777609,0.9720384,0.00005794938,0.003202721,0.000001680296,0.00232733,0.009777231,0.0007752544,0.0003852691,0.008748719,0.0001734734],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878709,0.0002822652,0.0003089281,0.01003815,0.00009801491,0.001113571,0.0001452935,0.0001159617,0.00002691986],"genre_scores_gemma":[0.9980928,0.00002519198,0.0006463415,0.0001628569,0.0002066554,0.0001564102,0.000584282,0.00002294087,0.0001024669],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07717358,"threshold_uncertainty_score":0.6549578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0516322117843698,"score_gpt":0.3040859879546243,"score_spread":0.2524537761702545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}